Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 85

1.

Infectious Disease Risks and Vulnerabilities in the Aftermath of an Environmental Disaster in Minas Gerais, Brazil.

Parekh FK, Yeh KB, Olinger G, Ribeiro FA.

Vector Borne Zoonotic Dis. 2020 Jan 16. doi: 10.1089/vbz.2019.2501. [Epub ahead of print]

PMID:
31944914
2.

Enhancing laboratory capacity during Ebola virus disease (EVD) heightened surveillance in Liberia: lessons learned and recommendations.

Katawera V, Kohar H, Mahmoud N, Raftery P, Wasunna C, Humrighouse B, Hardy P, Saindon J, Schoepp R, Makvandi M, Hensley L, Condell O, Durski K, Singaravelu S, Gahimbare L, Olinger G, Kateh F, Naidoo D, Nsubuga P, Formenty P, Nyenswah T, Coulibaly SO, Okeibunor JC, Talisuna A, Yahaya AA, Rajatonirina S, Williams D, Dahn B, Gasasira A, Fall IS.

Pan Afr Med J. 2019 May 29;33(Suppl 2):8. doi: 10.11604/pamj.supp.2019.33.2.17366. eCollection 2019.

3.

Inhibition of Ebola Virus by a Molecularly Engineered Banana Lectin.

Covés-Datson EM, Dyall J, DeWald LE, King SR, Dube D, Legendre M, Nelson E, Drews KC, Gross R, Gerhardt DM, Torzewski L, Postnikova E, Liang JY, Ban B, Shetty J, Hensley LE, Jahrling PB, Olinger GG Jr, White JM, Markovitz DM.

PLoS Negl Trop Dis. 2019 Jul 29;13(7):e0007595. doi: 10.1371/journal.pntd.0007595. eCollection 2019 Jul.

4.

Ebola Virus Isolation Using Huh-7 Cells has Methodological Advantages and Similar Sensitivity to Isolation Using Other Cell Types and Suckling BALB/c Laboratory Mice.

Logue J, Vargas Licona W, Cooper TK, Reeder B, Byrum R, Qin J, Deiuliis Murphy N, Cong Y, Bonilla A, Sword J, Weaver W, Kocher G, Olinger GG, Jahrling PB, Hensley LE, Bennett RS.

Viruses. 2019 Feb 16;11(2). pii: E161. doi: 10.3390/v11020161.

5.

The Convergence of High-Consequence Livestock and Human Pathogen Research and Development: A Paradox of Zoonotic Disease.

Michelotti JM, Yeh KB, Beckham TR, Colby MM, Dasgupta D, Zuelke KA, Olinger GG.

Trop Med Infect Dis. 2018 May 30;3(2). pii: E55. doi: 10.3390/tropicalmed3020055.

6.

In Vitro and In Vivo Activity of Amiodarone Against Ebola Virus.

Dyall J, Johnson JC, Hart BJ, Postnikova E, Cong Y, Zhou H, Gerhardt DM, Michelotti J, Honko AN, Kern S, DeWald LE, O'Loughlin KG, Green CE, Mirsalis JC, Bennett RS, Olinger GG Jr, Jahrling PB, Hensley LE.

J Infect Dis. 2018 Nov 22;218(suppl_5):S592-S596. doi: 10.1093/infdis/jiy345.

7.

Fully Human Immunoglobulin G From Transchromosomic Bovines Treats Nonhuman Primates Infected With Ebola Virus Makona Isolate.

Luke T, Bennett RS, Gerhardt DM, Burdette T, Postnikova E, Mazur S, Honko AN, Oberlander N, Byrum R, Ragland D, St Claire M, Janosko KB, Smith G, Glenn G, Hooper J, Dye J, Pal S, Bishop-Lilly KA, Hamilton T, Frey K, Bollinger L, Wada J, Wu H, Jiao JA, Olinger GG, Gunn B, Alter G, Khurana S, Hensley LE, Sullivan E, Jahrling PB.

J Infect Dis. 2018 Nov 22;218(suppl_5):S636-S648. doi: 10.1093/infdis/jiy377.

8.

The Calcium Channel Blocker Bepridil Demonstrates Efficacy in the Murine Model of Marburg Virus Disease.

DeWald LE, Dyall J, Sword JM, Torzewski L, Zhou H, Postnikova E, Kollins E, Alexander I, Gross R, Cong Y, Gerhardt DM, Johnson RF, Olinger GG Jr, Holbrook MR, Hensley LE, Jahrling PB.

J Infect Dis. 2018 Nov 22;218(suppl_5):S588-S591. doi: 10.1093/infdis/jiy332.

9.

Identification of Combinations of Approved Drugs With Synergistic Activity Against Ebola Virus in Cell Cultures.

Dyall J, Nelson EA, DeWald LE, Guha R, Hart BJ, Zhou H, Postnikova E, Logue J, Vargas WM, Gross R, Michelotti J, Deiuliis N, Bennett RS, Crozier I, Holbrook MR, Morris PJ, Klumpp-Thomas C, McKnight C, Mierzwa T, Shinn P, Glass PJ, Johansen LM, Jahrling PB, Hensley LE, Olinger GG Jr, Thomas C, White JM.

J Infect Dis. 2018 Nov 22;218(suppl_5):S672-S678. doi: 10.1093/infdis/jiy304.

10.

Avian Influenza Is a Catalyst for Economic and Political Destabilization in Iran.

Olinger GG, Yeh KB.

Health Secur. 2018 Mar/Apr;16(2):143. doi: 10.1089/hs.2018.0016. Epub 2018 Mar 15. No abstract available.

PMID:
29624487
11.

Testing therapeutics in cell-based assays: Factors that influence the apparent potency of drugs.

Postnikova E, Cong Y, DeWald LE, Dyall J, Yu S, Hart BJ, Zhou H, Gross R, Logue J, Cai Y, Deiuliis N, Michelotti J, Honko AN, Bennett RS, Holbrook MR, Olinger GG, Hensley LE, Jahrling PB.

PLoS One. 2018 Mar 22;13(3):e0194880. doi: 10.1371/journal.pone.0194880. eCollection 2018.

12.

Use of the Filovirus Animal Non-Clinical Group (FANG) Ebola virus immuno-assay requires fewer study participants to power a study than the Alpha Diagnostic International assay.

Logue J, Tuznik K, Follmann D, Grandits G, Marchand J, Reilly C, Sarro YDS, Pettitt J, Stavale EJ, Fallah M, Olinger GG, Bolay FK, Hensley LE.

J Virol Methods. 2018 May;255:84-90. doi: 10.1016/j.jviromet.2018.02.018. Epub 2018 Feb 23.

13.

Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies.

Dyall J, Gross R, Kindrachuk J, Johnson RF, Olinger GG Jr, Hensley LE, Frieman MB, Jahrling PB.

Drugs. 2017 Dec;77(18):1935-1966. doi: 10.1007/s40265-017-0830-1. Review.

14.

High dose sertraline monotherapy fails to protect rhesus macaques from lethal challenge with Ebola virus Makona.

Honko AN, Johnson JC, Marchand JS, Huzella L, Adams RD, Oberlander N, Torzewski LM, Bennett RS, Hensley LE, Jahrling PB, Olinger GG.

Sci Rep. 2017 Jul 19;7(1):5886. doi: 10.1038/s41598-017-06179-y.

15.

Therapeutics Against Filovirus Infection.

Connor J, Kobinger G, Olinger G.

Curr Top Microbiol Immunol. 2017;411:263-290. doi: 10.1007/82_2017_12. Review.

PMID:
28653190
16.

Nonhuman Primate Models of Ebola Virus Disease.

Bennett RS, Huzella LM, Jahrling PB, Bollinger L, Olinger GG Jr, Hensley LE.

Curr Top Microbiol Immunol. 2017;411:171-193. doi: 10.1007/82_2017_20. Review.

PMID:
28643203
17.

Vesicular Stomatitis Virus Pseudotyped with Ebola Virus Glycoprotein Serves as a Protective, Noninfectious Vaccine against Ebola Virus Challenge in Mice.

Lennemann NJ, Herbert AS, Brouillette R, Rhein B, Bakken RA, Perschbacher KJ, Cooney AL, Miller-Hunt CL, Ten Eyck P, Biggins J, Olinger G, Dye JM, Maury W.

J Virol. 2017 Aug 10;91(17). pii: e00479-17. doi: 10.1128/JVI.00479-17. Print 2017 Sep 1.

18.

The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection.

Nelson EA, Dyall J, Hoenen T, Barnes AB, Zhou H, Liang JY, Michelotti J, Dewey WH, DeWald LE, Bennett RS, Morris PJ, Guha R, Klumpp-Thomas C, McKnight C, Chen YC, Xu X, Wang A, Hughes E, Martin S, Thomas C, Jahrling PB, Hensley LE, Olinger GG Jr, White JM.

PLoS Negl Trop Dis. 2017 Apr 12;11(4):e0005540. doi: 10.1371/journal.pntd.0005540. eCollection 2017 Apr.

19.

Interferon-β and Interferon-γ Are Weak Inhibitors of Ebola Virus in Cell-Based Assays.

Dyall J, Hart BJ, Postnikova E, Cong Y, Zhou H, Gerhardt DM, Freeburger D, Michelotti J, Honko AN, DeWald LE, Bennett RS, Olinger GG Jr, Jahrling PB, Hensley LE.

J Infect Dis. 2017 May 1;215(9):1416-1420. doi: 10.1093/infdis/jix134.

20.

Evaluation of the Activity of Lamivudine and Zidovudine against Ebola Virus.

Cong Y, Dyall J, Hart BJ, DeWald LE, Johnson JC, Postnikova E, Zhou H, Gross R, Rojas O, Alexander I, Josleyn N, Zhang T, Michelotti J, Janosko K, Glass PJ, Flint M, McMullan LK, Spiropoulou CF, Mierzwa T, Guha R, Shinn P, Michael S, Klumpp-Thomas C, McKnight C, Thomas C, Eakin AE, O'Loughlin KG, Green CE, Catz P, Mirsalis JC, Honko AN, Olinger GG Jr, Bennett RS, Holbrook MR, Hensley LE, Jahrling PB.

PLoS One. 2016 Nov 30;11(11):e0166318. doi: 10.1371/journal.pone.0166318. eCollection 2016.

Supplemental Content

Loading ...
Support Center